LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・MediciNova Inc

MediciNova Inc

Затворен

СекторЗдравеопазване

1.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.32

Ключови измерители
By Trading Economics
Приходи	216K -2.6M
Продажби	35K 187K
EPS	-0.05
Марж на печалбата	-1,383.144
Служители	6
EBITDA	63K -2.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+506.06% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2M 67M
Предишно отваряне	1.31
Предишно затваряне	1.31

Настроения в новините

By Acuity

26%

74%

59 / 344 Класиране в Healthcare

MediciNova Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.06.2026 г., 21:51 ч. UTC

Значими двигатели на пазара

Merlin Shares Rally After Defense Department's Design Review Wraps

4.06.2026 г., 23:46 ч. UTC

Пазарно говорене

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4.06.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4.06.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4.06.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia to Enter Trading Halt

4.06.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.06.2026 г., 23:08 ч. UTC

Пазарно говорене

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4.06.2026 г., 22:41 ч. UTC

Пазарно говорене

Australia Shares Set to Rise at the Open -- Market Talk

4.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4.06.2026 г., 20:16 ч. UTC

Пазарно говорене

Mexican Demand Indicators Show Signs of Life -- Market Talk

4.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4.06.2026 г., 19:46 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4.06.2026 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4.06.2026 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4.06.2026 г., 18:47 ч. UTC

Придобивния, сливания и поглъщания

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4.06.2026 г., 18:38 ч. UTC

Печалби

Money Quote: Tech Weakness in Context -- WSJ

4.06.2026 г., 18:24 ч. UTC

Печалби

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 17:09 ч. UTC

Пазарно говорене

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4.06.2026 г., 16:58 ч. UTC

Печалби

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 16:46 ч. UTC

Пазарно говорене

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4.06.2026 г., 16:38 ч. UTC

Печалби

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

4.06.2026 г., 16:13 ч. UTC

Пазарно говорене

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4.06.2026 г., 16:11 ч. UTC

Пазарно говорене

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4.06.2026 г., 15:56 ч. UTC

Пазарно говорене

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MediciNova Inc Прогноза

Ценова цел

By TipRanks

506.06% нагоре

12-месечна прогноза

Среден 8 USD 506.06%

Висок 10 USD

Нисък 6 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за MediciNova Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на MediciNova Inc през последните 3 месеца.

Настроение

By Acuity

59 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.